Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, Y.
Right arrow Articles by Mellors, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, Y.
Right arrow Articles by Mellors, A.

Clinical Cancer Research, Vol 1, Issue 10 1223-1232, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients

Y Xu, DC Gaudette, JD Boynton, A Frankel, XJ Fang, A Sharma, J Hurteau, G Casey, A Goodbody and A Mellors
Oncology Research, Toronto General Hospital, Toronto, Ontario M5G 2C4, Allelix Biopharmaceuticals Inc., Mississauga, Ontario L4V IPI, Canada.

Ascites from ovarian cancer patients contain potent growth-promoting activity toward human ovarian cancer cells both in vitro and in vivo. This activity is associated with rapid increases in cytosolic free calcium ([Ca2+]i) as a consequence of phosphoinositide hydrolysis. In this study, we describe the purification, characterization, and identification of an ovarian cancer activating factor (OCAF) from ascites of ovarian cancer patients. We have isolated OCAF by a combination of solvent extraction, silica gel chromatography, and TLC. Mass spectral analysis, phospholipase sensitivity, and gas chromatographic behavior of purified OCAF indicate that OCAF is composed of various species of lysophosphatidic acid (LPA), including LPAs with polyunsaturated fatty acyl chains (linoleic, arachidonic, and docosahexaenoic acids). However, OCAF is more potent than sn-1 palmitoyl, oleoyl, or stearoyl LPA in increasing [Ca2+]i in ovarian cancer cells. The ability of OCAF to alter [Ca2+]i is sensitive to the effects of lipoxidase, whereas the activity of sn-1 oleoyl, stearoyl, or palmitoyl LPA is not, suggesting that polyunsaturated bonds in the fatty acyl chain of OCAF may account for its increased ability to activate ovarian cancer cells. Furthermore, a sn-2 linoleoyl LPA generated by phospholipase A1 treatment of synthetic phosphatidic acid is much more active than are sn-1 palmitoyl, stearoyl, or oleoyl LPA in increasing [Ca2+]i in ovarian cancer cells. Taken together, these data suggest that the ability of OCAF to increase cellular calcium may reside in the structure and/or location of the fatty acyl chain of LPA. Purified OCAF, at concentrations similar to those present in ascites from ovarian cancer patients, was sufficient to induce proliferation of ovarian cancer cells, as indicated by thymidine incorporation, reduction of 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, or colony formation. However, even at optimal concentrations of OCAF, proliferation was lower than that induced by FCS or ascites from ovarian cancer patients, indicating that, although OCAF may be a major regulator of ovarian cancer cells in vivo, it is not the sole mediator present in ascites, and it likely functions in concert with other growth factor activities.


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
X. Ye
Lysophospholipid signaling in the function and pathology of the reproductive system
Hum. Reprod. Update, September 1, 2008; 14(5): 519 - 536.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. J. Valentine, J. I. Fells, D. H. Perygin, S. Mujahid, K. Yokoyama, Y. Fujiwara, R. Tsukahara, J. R. Van Brocklyn, A. L. Parrill, and G. Tigyi
Subtype-specific Residues Involved in Ligand Activation of the Endothelial Differentiation Gene Family Lysophosphatidic Acid Receptors
J. Biol. Chem., May 2, 2008; 283(18): 12175 - 12187.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
E. S. Jeon, H. J. Moon, M. J. Lee, H. Y. Song, Y. M. Kim, M. Cho, D.-S. Suh, M.-S. Yoon, C. L. Chang, J. S. Jung, et al.
Cancer-Derived Lysophosphatidic Acid Stimulates Differentiation of Human Mesenchymal Stem Cells to Myofibroblast-Like Cells
Stem Cells, March 1, 2008; 26(3): 789 - 797.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed
Normalization of the Ovarian Cancer Microenvironment by SPARC
Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Satpathy, L. Cao, R. Pincheira, R. Emerson, R. Bigsby, H. Nakshatri, and D. Matei
Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase
Cancer Res., August 1, 2007; 67(15): 7194 - 7202.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T.-V. Do, J. C. Symowicz, D. M. Berman, L. A. Liotta, E. F. Petricoin III, M. S. Stack, and D. A. Fishman
Lysophosphatidic Acid Down-Regulates Stress Fibers and Up-Regulates Pro-Matrix Metalloproteinase-2 Activation in Ovarian Cancer Cells
Mol. Cancer Res., February 1, 2007; 5(2): 121 - 131.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Lee, S. Y. Park, E. K. Lee, C. G. Park, H. C. Chung, S. Y. Rha, Y. K. Kim, G.-U. Bae, B. K. Kim, J.-W. Han, et al.
Activation of Hypoxia-Inducible Factor-1{alpha} Is Necessary for Lysophosphatidic Acid-Induced Vascular Endothelial Growth Factor Expression.
Clin. Cancer Res., November 1, 2006; 12(21): 6351 - 6358.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Guo, E. A. Kasbohm, P. Arora, C. J. Sample, B. Baban, N. Sud, P. Sivashanmugam, N. H. Moniri, and Y. Daaka
Expression and Function of Lysophosphatidic Acid LPA1 Receptor in Prostate Cancer Cells
Endocrinology, October 1, 2006; 147(10): 4883 - 4892.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-S. Kim, S. Sengupta, M. Berk, Y.-G. Kwak, P. F. Escobar, J. Belinson, S. C. Mok, and Y. Xu
Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo
Cancer Res., August 15, 2006; 66(16): 7983 - 7990.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Ren, Y.-j. Xiao, L. S. Singh, X. Zhao, Z. Zhao, L. Feng, T. M. Rose, G. D. Prestwich, and Y. Xu
Lysophosphatidic Acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells.
Cancer Res., March 15, 2006; 66(6): 3006 - 3014.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tanaka, S. Miyamoto, S. O. Suzuki, E. Oki, H. Yagi, K. Sonoda, A. Yamazaki, H. Mizushima, Y. Maehara, E. Mekada, et al.
Clinical Significance of Heparin-Binding Epidermal Growth Factor-Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4783 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
T. Maffucci, F. T. Cooke, F. M. Foster, C. J. Traer, M. J. Fry, and M. Falasca
Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration
J. Cell Biol., June 6, 2005; 169(5): 789 - 799.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Li, X. Ye, C. Mahanivong, D. Bian, J. Chun, and S. Huang
Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells
J. Biol. Chem., March 18, 2005; 280(11): 10564 - 10571.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Symowicz, B. P. Adley, M. M.M. Woo, N. Auersperg, L. G. Hudson, and M. S. Stack
Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells
Cancer Res., March 15, 2005; 65(6): 2234 - 2242.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
K. Itagaki, K. B. Kannan, and C. J. Hauser
Lysophosphatidic acid triggers calcium entry through a non-store-operated pathway in human neutrophils
J. Leukoc. Biol., February 1, 2005; 77(2): 181 - 189.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C.-H. Chou, L.-H. Wei, M.-L. Kuo, Y.-J. Huang, K.-P. Lai, C.-A. Chen, and C.-Y. Hsieh
Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-{kappa}B pathway by lysophosphatidic acid, an ovarian cancer-activating factor
Carcinogenesis, January 1, 2005; 26(1): 45 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
T. Tanaka, H. Tsutsui, K. Hirano, T. Koike, A. Tokumura, and K. Satouchi
Quantitative analysis of lysophosphatidic acid by time-of-flight mass spectrometry using a phosphate-capture molecule
J. Lipid Res., November 1, 2004; 45(11): 2145 - 2150.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Miyamoto, M. Hirata, A. Yamazaki, T. Kageyama, H. Hasuwa, H. Mizushima, Y. Tanaka, H. Yagi, K. Sonoda, M. Kai, et al.
Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy
Cancer Res., August 15, 2004; 64(16): 5720 - 5727.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. Sutphen, Y. Xu, G. D. Wilbanks, J. Fiorica, E. C. Grendys Jr., J. P. LaPolla, H. Arango, M. S. Hoffman, M. Martino, K. Wakeley, et al.
Lysophospholipids Are Potential Biomarkers of Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1185 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Fang, S. Yu, R. C. Bast, S. Liu, H.-J. Xu, S.-X. Hu, R. LaPushin, F. X. Claret, B. B. Aggarwal, Y. Lu, et al.
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
J. Biol. Chem., March 5, 2004; 279(10): 9653 - 9661.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Yamada, K. Sato, M. Komachi, E. Malchinkhuu, M. Tobo, T. Kimura, A. Kuwabara, Y. Yanagita, T. Ikeya, Y. Tanahashi, et al.
Lysophosphatidic Acid (LPA) in Malignant Ascites Stimulates Motility of Human Pancreatic Cancer Cells through LPA1
J. Biol. Chem., February 20, 2004; 279(8): 6595 - 6605.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. Ohta, K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, et al.
Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors
Mol. Pharmacol., October 1, 2003; 64(4): 994 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
C. Luquain, A. Singh, L. Wang, V. Natarajan, and A. J. Morris
Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells
J. Lipid Res., October 1, 2003; 44(10): 1963 - 1975.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Stahle, C. Veit, U. Bachfischer, K. Schierling, B. Skripczynski, A. Hall, P. Gierschik, and K. Giehl
Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK
J. Cell Sci., September 15, 2003; 116(18): 3835 - 3846.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Tanyi, Y. Hasegawa, R. Lapushin, A. J. Morris, J. K. Wolf, A. Berchuck, K. Lu, D. I. Smith, K. Kalli, L. C. Hartmann, et al.
Role of Decreased Levels of Lipid Phosphate Phosphatase-1 in Accumulation of Lysophosphatidic Acid in Ovarian Cancer
Clin. Cancer Res., September 1, 2003; 9(10): 3534 - 3545.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Noguchi, S. Ishii, and T. Shimizu
Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg Family
J. Biol. Chem., July 3, 2003; 278(28): 25600 - 25606.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y.-L. Hu, C. Albanese, R. G. Pestell, and R. B. Jaffe
Dual Mechanisms for Lysophosphatidic Acid Stimulation of Human Ovarian Carcinoma Cells
J Natl Cancer Inst, May 21, 2003; 95(10): 733 - 740.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Ferry, E. Tellier, A. Try, S. Gres, I. Naime, M. F. Simon, M. Rodriguez, J. Boucher, I. Tack, S. Gesta, et al.
Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation. UP-REGULATED EXPRESSION WITH ADIPOCYTE DIFFERENTIATION AND OBESITY
J. Biol. Chem., May 9, 2003; 278(20): 18162 - 18169.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Shida, J. Kitayama, H. Yamaguchi, Y. Okaji, N. H. Tsuno, T. Watanabe, Y. Takuwa, and H. Nagawa
Lysophosphatidic Acid (LPA) Enhances the Metastatic Potential of Human Colon Carcinoma DLD1 Cells through LPA1
Cancer Res., April 1, 2003; 63(7): 1706 - 1711.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Hasegawa, J. R. Erickson, G. J. Goddard, S. Yu, S. Liu, K. W. Cheng, A. Eder, K. Bandoh, J. Aoki, R. Jarosz, et al.
Identification of a Phosphothionate Analogue of Lysophosphatidic Acid (LPA) as a Selective Agonist of the LPA3 Receptor
J. Biol. Chem., March 28, 2003; 278(14): 11962 - 11969.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Tanyi, A. J. Morris, J. K. Wolf, X. Fang, Y. Hasegawa, R. Lapushin, N. Auersperg, Y. J. Sigal, R. A. Newman, E. A. Felix, et al.
The Human Lipid Phosphate Phosphatase-3 Decreases the Growth, Survival, and Tumorigenesis of Ovarian Cancer Cells: Validation of the Lysophosphatidic Acid Signaling Cascade as a Target for Therapy in Ovarian Cancer
Cancer Res., March 1, 2003; 63(5): 1073 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. M. McIntyre, A. V. Pontsler, A. R. Silva, A. St. Hilaire, Y. Xu, J. C. Hinshaw, G. A. Zimmerman, K. Hama, J. Aoki, H. Arai, et al.
From the Cover: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist
PNAS, January 7, 2003; 100(1): 131 - 136.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. N. van Leeuwen, C. Olivo, S. Grivell, B. N. G. Giepmans, J. G. Collard, and W. H. Moolenaar
Rac Activation by Lysophosphatidic Acid LPA1 Receptors through the Guanine Nucleotide Exchange Factor Tiam1
J. Biol. Chem., January 3, 2003; 278(1): 400 - 406.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
T. Sugiura, S. Nakane, S. Kishimoto, K. Waku, Y. Yoshioka, and A. Tokumura
Lysophosphatidic acid, a growth factor-like lipid, in the saliva
J. Lipid Res., December 1, 2002; 43(12): 2049 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. F. Eisen and H. A. Brown
Selective Estrogen Receptor (ER) Modulators Differentially Regulate Phospholipase D Catalytic Activity in ER-Negative Breast Cancer Cells
Mol. Pharmacol., October 1, 2002; 62(4): 911 - 920.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Sonoda, J. Aoki, T. Hiramatsu, M. Ishida, K. Bandoh, Y. Nagai, R. Taguchi, K. Inoue, and H. Arai
A Novel Phosphatidic Acid-selective Phospholipase A1 That Produces Lysophosphatidic Acid
J. Biol. Chem., September 6, 2002; 277(37): 34254 - 34263.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. M. Baudhuin, K. L. Cristina, J. Lu, and Y. Xu
Akt Activation Induced by Lysophosphatidic Acid and Sphingosine-1-phosphate Requires Both Mitogen-Activated Protein Kinase Kinase and p38 Mitogen-Activated Protein Kinase and Is Cell-Line Specific
Mol. Pharmacol., September 1, 2002; 62(3): 660 - 671.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
M. Umezu-Goto, Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G. B. Mills, K. Inoue, J. Aoki, et al.
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production
J. Cell Biol., July 22, 2002; 158(2): 227 - 233.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. L. Baker, P. Morrison, B. Miller, C. A. Riely, B. Tolley, A. M. Westermann, J. M. G. Bonfrer, E. Bais, W. H. Moolenaar, and G. Tigyi
Plasma Lysophosphatidic Acid Concentration and Ovarian Cancer
JAMA, June 19, 2002; 287(23): 3081 - 3082.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. Gesta, M.-F. Simon, A. Rey, D. Sibrac, A. Girard, M. Lafontan, P. Valet, and J. S. Saulnier-Blache
Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis
J. Lipid Res., June 1, 2002; 43(6): 904 - 910.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
X. Fang, S. Yu, J. L. Tanyi, Y. Lu, J. R. Woodgett, and G. B. Mills
Convergence of Multiple Signaling Cascades at Glycogen Synthase Kinase 3: Edg Receptor-Mediated Phosphorylation and Inactivation by Lysophosphatidic Acid through a Protein Kinase C-Dependent Intracellular Pathway
Mol. Cell. Biol., April 1, 2002; 22(7): 2099 - 2110.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
L. T. Budnik and A. K. Mukhopadhyay
Lysophosphatidic Acid and Its Role in Reproduction
Biol Reprod, April 1, 2002; 66(4): 859 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. D. Oberst, M. D. Johnson, R. B. Dickson, C.-Y. Lin, B. Singh, M. Stewart, A. Williams, A. al-Nafussi, J. F. Smyth, H. Gabra, et al.
Expression of the Serine Protease Matriptase and Its Inhibitor HAI-1 in Epithelial Ovarian Cancer: Correlation with Clinical Outcome and Tumor Clinicopathological Parameters
Clin. Cancer Res., April 1, 2002; 8(4): 1101 - 1107.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. Lu, Y.-j. Xiao, L. M. Baudhuin, G. Hong, and Y. Xu
Role of ether-linked lysophosphatidic acids in ovarian cancer cells
J. Lipid Res., March 1, 2002; 43(3): 463 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. E. Heise, W. L. Santos, A. M. Schreihofer, B. H. Heasley, Y. V. Mukhin, T. L. Macdonald, and K. R. Lynch
Activity of 2-Substituted Lysophosphatidic Acid (LPA) Analogs at LPA Receptors: Discovery of a LPA1/LPA3 Receptor Antagonist
Mol. Pharmacol., December 1, 2001; 60(6): 1173 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. J. Fischer, N. Nusser, T. Virag, K. Yokoyama, D.-a. Wang, D. L. Baker, D. Bautista, A. L. Parrill, and G. Tigyi
Short-Chain Phosphatidates Are Subtype-Selective Antagonists of Lysophosphatidic Acid Receptors
Mol. Pharmacol., October 1, 2001; 60(4): 776 - 784.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y.-L. Hu, M.-K. Tee, E. J. Goetzl, N. Auersperg, G. B. Mills, N. Ferrara, and R. B. Jaffe
Lysophosphatidic Acid Induction of Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells
J Natl Cancer Inst, May 16, 2001; 93(10): 762 - 767.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. J. A. Contos, I. Ishii, and J. Chun
Lysophosphatidic Acid Receptors
Mol. Pharmacol., April 13, 2001; 58(6): 1188 - 1196.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology
Endocr. Rev., April 1, 2001; 22(2): 255 - 288.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
D. A. Fishman, Y. Liu, S. M. Ellerbroek, and M. S. Stack
Lysophosphatidic Acid Promotes Matrix Metalloproteinase (MMP) Activation and MMP-dependent Invasion in Ovarian Cancer Cells
Cancer Res., April 1, 2001; 61(7): 3194 - 3199.
[Abstract] [Full Text]

Home page
 Reproductive SciencesHome page
Y. Xu, Y.-j. Xiao, L. M. Baudhuin, and B. M. Schwartz
The Role and Clinical Applications of Bioactive Lysolipids in Ovarian Cancer
Reproductive Sciences, January 1, 2001; 8(1): 1 - 13.
[Abstract] [PDF]

Home page
 J. Lipid Res.Home page
J. S. Saulnier-Blache, A. Girard, M.-F. Simon, M. Lafontan, and P. Valet
A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification
J. Lipid Res., December 1, 2000; 41(12): 1947 - 1951.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Imai, T. Furui, T. Tamaya, and G. B. Mills
A Gonadotropin-Releasing Hormone-Responsive Phosphatase Hydrolyses Lysophosphatidic Acid within the Plasma Membrane of Ovarian Cancer Cells
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3370 - 3375.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
A. M. Eder, T. Sasagawa, M. Mao, J. Aoki, and G. B. Mills
Constitutive and Lysophosphatidic Acid (LPA)-induced LPA Production: Role of Phospholipase D and Phospholipase A2
Clin. Cancer Res., June 1, 2000; 6(6): 2482 - 2491.
[Abstract] [Full Text]

Home page
 Ann. N. Y. Acad. Sci.Home page
W. H. MOOLENAAR
Development of Our Current Understanding of Bioactive Lysophospholipids
Ann. N.Y. Acad. Sci., April 1, 2000; 905(1): 1 - 10.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
C. PAGES, A. GIRARD, O. JEANNETON, P. BARBE, C. WOLF, M. LAFONTAN, P. VALET, and J. S. SAULNIER-BLACHE
LPA as a Paracrine Mediator of Adipocyte Growth and Function
Ann. N.Y. Acad. Sci., April 1, 2000; 905(1): 159 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
X. FANG, D. GAUDETTE, T. FURUI, M. MAO, V. ESTRELLA, A. EDER, T. PUSTILNIK, T. SASAGAWA, R. LAPUSHIN, S. YU, et al.
Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer
Ann. N.Y. Acad. Sci., April 1, 2000; 905(1): 188 - 208.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
Y. XIAO, Y. CHEN, A. W. KENNEDY, J. BELINSON, and Y. XU
Evaluation of Plasma Lysophospholipids for Diagnostic Significance Using Electrospray Ionization Mass Spectrometry (ESI-MS) Analyses
Ann. N.Y. Acad. Sci., April 1, 2000; 905(1): 242 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Furui, R. LaPushin, M. Mao, H. Khan, S. R. Watt, M.-A. V. Watt, Y. Lu, X. Fang, S. Tsutsui, Z. H. Siddik, et al.
Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikisin Ovarian Cancer Cells in a Lysophosphatidic Acid-independent Manner
Clin. Cancer Res., December 1, 1999; 5(12): 4308 - 4318.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. B. Pustilnik, V. Estrella, J. R. Wiener, M. Mao, A. Eder, M.-A. V. Watt, R. C. Bast Jr., and G. B. Mills
Lysophosphatidic Acid Induces Urokinase Secretion by Ovarian Cancer Cells
Clin. Cancer Res., November 1, 1999; 5(11): 3704